Related references
Note: Only part of the references are listed.V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma
Stephanie Muller et al.
MODERN PATHOLOGY (2020)
The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma
Heike Loeser et al.
ONCOIMMUNOLOGY (2019)
VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma
Ming Zhang et al.
BMC CANCER (2018)
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
Lawrence F. Kuklinski et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma
G. J. Hanna et al.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2018)
Density and location of CD3+ and CD8+ tumor-infiltrating lymphocytes correlate with prognosis of oral squamous cell carcinoma
Chen Zhou et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2018)
Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma
Rebecca Hoesli et al.
ORAL ONCOLOGY (2018)
Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer
Hong Liao et al.
ONCOLOGY LETTERS (2018)
Tumor-infiltrating CD8+and FOXP3+lymphocytes before and after neoadjuvant chemotherapy in cervical cancer
Yun Liang et al.
DIAGNOSTIC PATHOLOGY (2018)
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer
Franz Villarroel-Espindola et al.
CLINICAL CANCER RESEARCH (2018)
High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma A cohort study
Sheng-Lan Ye et al.
MEDICINE (2017)
The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer
Jun Li et al.
ONCOTARGET (2017)
Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer
Astrid De Meulenaere et al.
ONCOTARGET (2017)
Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes
Qian Zhu et al.
ONCOIMMUNOLOGY (2017)
The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Christine Boeger et al.
ONCOIMMUNOLOGY (2017)
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Ellen L. Goode et al.
JAMA ONCOLOGY (2017)
Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study
Hayam E. Rashed et al.
TURKISH JOURNAL OF PATHOLOGY (2017)
Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma
Lei Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma
Yasunao Kogashiwa et al.
ANTICANCER RESEARCH (2017)
Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
Maria Vassilakopoulou et al.
CLINICAL CANCER RESEARCH (2016)
Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma
Nghia Nguyen et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Andrew Gabrielson et al.
CANCER IMMUNOLOGY RESEARCH (2016)
VISTA Is an Immune Checkpoint Molecule for Human T Cells
J. Louise Lines et al.
CANCER RESEARCH (2014)
VISTA Regulates the Development of Protective Antitumor Immunity
Isabelle Le Mercier et al.
CANCER RESEARCH (2014)
VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
J. Louise Lines et al.
CANCER IMMUNOLOGY RESEARCH (2014)
PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
Cecile Badoual et al.
CANCER RESEARCH (2013)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Li Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Share Paper
